UMR9019, Genome Integrity and Cancers, CNRS, Villejuif, France
Search for other papers by Camille Buffet in
Google Scholar
PubMed
Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed
CHU Nantes/ICO, Saint-Herblain, France
Search for other papers by Françoise Kraeber-Bodéré in
Google Scholar
PubMed
CHU Nantes/ICO, Saint-Herblain, France
Search for other papers by Caroline Bodet-Milin in
Google Scholar
PubMed
Université de Paris, Paris, France
Search for other papers by Laure Cabanes in
Google Scholar
PubMed
Department of Radiology, AP-HP, Hôpital Cochin, Paris, France
Search for other papers by Anthony Dohan in
Google Scholar
PubMed
Search for other papers by Pascal Leprince in
Google Scholar
PubMed
Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy Institute, Villejuif, France
Search for other papers by Martin Schlumberger in
Google Scholar
PubMed
Department of Medical Oncology, AP-HP, Hôpital Cochin, Paris, France
Search for other papers by Olivier Huillard in
Google Scholar
PubMed
Université de Paris, Paris, France
Department of Endocrinology, AP-HP, Hôpital Cochin, Paris, France
Search for other papers by Lionel Groussin in
Google Scholar
PubMed
Established Facts Cardiac metastases from thyroid cancers are uncommon with a poor prognosis. Novel Insights Our work highlights 2 major points: The diagnostic challenge represented by cardiac metastases: in both
Search for other papers by Roberto Negro in
Google Scholar
PubMed
Biomedical Sciences, Università della Svizzera Italiana (USI), Lugano, Switzerland
Search for other papers by Pierpaolo Trimboli in
Google Scholar
PubMed
In the present issue of European Thyroid Journal , Papini et al. [ 1 ] published guidelines for the use of thermal ablation (TA) in benign thyroid nodules, sponsored by the European Thyroid Association (ETA). The guidelines highlight the state
Thyroid Diseases Center, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil
Fleury Medicina e Saúde, São Paulo, Brazil
Search for other papers by Cláudia C.D. Nakabashi in
Google Scholar
PubMed
Search for other papers by Teresa S. Kasamatsu in
Google Scholar
PubMed
Search for other papers by Felipe Crispim in
Google Scholar
PubMed
Search for other papers by Claudia A. Yamazaki in
Google Scholar
PubMed
Thyroid Diseases Center, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil
Search for other papers by Cléber P. Camacho in
Google Scholar
PubMed
Thyroid Diseases Center, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil
Search for other papers by Danielle M. Andreoni in
Google Scholar
PubMed
Thyroid Diseases Center, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil
Search for other papers by Rosalia P. Padovani in
Google Scholar
PubMed
Thyroid Diseases Center, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil
Search for other papers by Elza S. Ikejiri in
Google Scholar
PubMed
Thyroid Diseases Center, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil
Search for other papers by Maria C.O.M. Mamone in
Google Scholar
PubMed
Search for other papers by Flávia C. Aldighieri in
Google Scholar
PubMed
Search for other papers by Jairo Wagner in
Google Scholar
PubMed
Thyroid Diseases Center, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil
Search for other papers by Jairo T. Hidal in
Google Scholar
PubMed
Fleury Medicina e Saúde, São Paulo, Brazil
Search for other papers by José G.H. Vieira in
Google Scholar
PubMed
Thyroid Diseases Center, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil
Fleury Medicina e Saúde, São Paulo, Brazil
Search for other papers by Rosa P.M. Biscolla in
Google Scholar
PubMed
Thyroid Diseases Center, Instituto Israelita de Ensino e Pesquisa Albert Einstein, São Paulo, Brazil
Fleury Medicina e Saúde, São Paulo, Brazil
Search for other papers by Rui M.B. Maciel in
Google Scholar
PubMed
Introduction Patients with differentiated thyroid carcinoma (DTC) generally have a very good prognosis, with 10-year overall mortality of less than 4% [ 1 ]. However, persistent or recurrent disease, which is mainly loco-regional, occurs in
Search for other papers by Zhongli Chen in
Google Scholar
PubMed
Search for other papers by Robin P Peeters in
Google Scholar
PubMed
Search for other papers by Wesley Flach in
Google Scholar
PubMed
Search for other papers by Linda J de Rooij in
Google Scholar
PubMed
Search for other papers by Sena Yildiz in
Google Scholar
PubMed
DZHK (German Center for Cardiovascular Research), Partner Site Greifswald, Greifswald, Germany
Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany
Search for other papers by Alexander Teumer in
Google Scholar
PubMed
Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Germany
Search for other papers by Matthias Nauck in
Google Scholar
PubMed
Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands
Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
Search for other papers by Rosalie B T M Sterenborg in
Google Scholar
PubMed
Search for other papers by Joost H W Rutten in
Google Scholar
PubMed
Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands
Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
Search for other papers by Marco Medici in
Google Scholar
PubMed
Search for other papers by W Edward Visser in
Google Scholar
PubMed
Search for other papers by Marcel E Meima in
Google Scholar
PubMed
Introduction Thyroid hormone (TH) is important for development, metabolism and tissue homeostasis. The intracellular bioavailability of TH is dependent on plasma membrane transporters that mediate TH influx and efflux ( 1 ). The relevance of
Search for other papers by Francesco Boi in
Google Scholar
PubMed
Search for other papers by Fabiana Pani in
Google Scholar
PubMed
Search for other papers by Stefano Mariotti in
Google Scholar
PubMed
immune response against thyroid autoantigens, with the contribution of genetic and environmental factors [ 1 - 3 ]. Thyroid nodules (TN) are very frequently observed, but only a small part of them are malignant tumors, mostly (85%) papillary thyroid
Search for other papers by Stine Linding Andersen in
Google Scholar
PubMed
Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
Search for other papers by Stig Andersen in
Google Scholar
PubMed
Key Points Overt thyroid disease should be diagnosed and treated in nonpregnant and pregnant patients. Subclinical thyroid disease management is debatable in nonpregnant and pregnant patients. Smaller aberrations in thyroid
Search for other papers by Jan Jiskra in
Google Scholar
PubMed
Search for other papers by Jiří Horáček in
Google Scholar
PubMed
Search for other papers by Sylvie Špitálníková in
Google Scholar
PubMed
Search for other papers by Jan Paleček in
Google Scholar
PubMed
Search for other papers by Zdeňka Límanová in
Google Scholar
PubMed
Search for other papers by Jan Krátký in
Google Scholar
PubMed
Search for other papers by Drahomíra Springer in
Google Scholar
PubMed
Search for other papers by Kristýna Žabková in
Google Scholar
PubMed
Search for other papers by Hana Vítková in
Google Scholar
PubMed
Introduction While the prevalence of thyroid nodules during pregnancy in areas with mild to moderate iodine deficiency varies between 3 and 21% ( 1 , 2 ) and increases with increasing parity ( 3 ), data from areas with sufficient iodine
Search for other papers by Hirosuke Danno in
Google Scholar
PubMed
Search for other papers by Eijun Nishihara in
Google Scholar
PubMed
Search for other papers by Kazuyoshi Kousaka in
Google Scholar
PubMed
Search for other papers by Tomohiko Nakamura in
Google Scholar
PubMed
Search for other papers by Toshihiko Kasahara in
Google Scholar
PubMed
Search for other papers by Takumi Kudo in
Google Scholar
PubMed
Search for other papers by Mitsuru Ito in
Google Scholar
PubMed
Search for other papers by Shuji Fukata in
Google Scholar
PubMed
Search for other papers by Mitsushige Nishikawa in
Google Scholar
PubMed
Search for other papers by Akira Miyauchi in
Google Scholar
PubMed
Introduction The Marine-Lenhart syndrome (MLS), first described by Charkes in 1972 [ 1 ], is now commonly defined as “a combination of Graves’ disease and autonomous functioning thyroid nodule(s) (AFTN)” [ 2 - 4 ]. Typical scintigraphic images
Search for other papers by Emilio Fiore in
Google Scholar
PubMed
Search for other papers by Francesco Latrofa in
Google Scholar
PubMed
Search for other papers by Paolo Vitti in
Google Scholar
PubMed
Introduction This review will focus on two different, related topics: (a) iodine and thyroid autoimmunity and (b) thyroid autoimmunity and papillary thyroid carcinoma (PTC). We will review the latest data on these issues and describe our more
Search for other papers by Zohar Steinberg Ben-Zeev in
Google Scholar
PubMed
Search for other papers by Marina Peniakov in
Google Scholar
PubMed
Search for other papers by Clari Felszer in
Google Scholar
PubMed
Search for other papers by Scott A Weiner in
Google Scholar
PubMed
Search for other papers by Avishay Lahad in
Google Scholar
PubMed
Search for other papers by Shlomo Almashanu in
Google Scholar
PubMed
The Rappaport Faculty of Medicine, Technion, Institute of Technology, Haifa, Israel
Search for other papers by Yardena Tenenbaum Rakover in
Google Scholar
PubMed
Introduction Maternal thyroid diseases are considered a risk factor for abnormal thyroid function at birth ( 1 , 2 , 3 , 4 , 5 ), as well as for long-term morbidity in offspring ( 1 , 6 , 7 , 8 , 9 , 10 , 11 ). Maternal